An experimental drug for Alzheimer’s disease is showing early promise.
Drug maker Biogen developed the drug called "Aducanumab" and funded this latest research. The drug was found to significantly reduce plaques in the brain, which experts believe play a critical role in the development of Alzheimer’s.
Experts are cautious, saying the study was too small to prove any real clinical benefit. Previous drugs have been encouraging in early trials, then later failed.
Still, Dr. Natalie Azar with the NYU Langone Medical Center says this research is promising.
"These plaques can start to surface years, even like a decade before symptoms start. So imagine if you could take a population of people who are at risk, either by screening or genetic risk, and give them this drug that early and prevent the plaques from ever developing,” Dr. Azar said” Could that then translate into a truly meaningful treatment for Alzheimer’s?"
Researchers hope to have an answer to that question when the research is finished, likely in the year 2020.
- Harvard researchers unveil new Alzheimer's theory
- New information shows toll on Alzheimer's caretakers
- Q & A: What is early onset Alzheimer's disease?